Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists: Synthesis, pharmacology, and molecular modeling

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists : Synthesis, pharmacology, and molecular modeling. / Frølund, Bente; Jørgensen, Anne T.; Tagmose, Lena; Stensbøl, Tine B.; Vestergaard, Henrik T.; Engblom, Christine; Kristiansen, Uffe; Sanchez, Connie; Krogsgaard-Larsen, Povl; Liljefors, Tommy.

In: Journal of Medicinal Chemistry, Vol. 45, No. 12, 06.06.2002, p. 2454-2468.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Frølund, B, Jørgensen, AT, Tagmose, L, Stensbøl, TB, Vestergaard, HT, Engblom, C, Kristiansen, U, Sanchez, C, Krogsgaard-Larsen, P & Liljefors, T 2002, 'Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists: Synthesis, pharmacology, and molecular modeling', Journal of Medicinal Chemistry, vol. 45, no. 12, pp. 2454-2468. https://doi.org/10.1021/jm020027o

APA

Frølund, B., Jørgensen, A. T., Tagmose, L., Stensbøl, T. B., Vestergaard, H. T., Engblom, C., Kristiansen, U., Sanchez, C., Krogsgaard-Larsen, P., & Liljefors, T. (2002). Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists: Synthesis, pharmacology, and molecular modeling. Journal of Medicinal Chemistry, 45(12), 2454-2468. https://doi.org/10.1021/jm020027o

Vancouver

Frølund B, Jørgensen AT, Tagmose L, Stensbøl TB, Vestergaard HT, Engblom C et al. Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists: Synthesis, pharmacology, and molecular modeling. Journal of Medicinal Chemistry. 2002 Jun 6;45(12):2454-2468. https://doi.org/10.1021/jm020027o

Author

Frølund, Bente ; Jørgensen, Anne T. ; Tagmose, Lena ; Stensbøl, Tine B. ; Vestergaard, Henrik T. ; Engblom, Christine ; Kristiansen, Uffe ; Sanchez, Connie ; Krogsgaard-Larsen, Povl ; Liljefors, Tommy. / Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists : Synthesis, pharmacology, and molecular modeling. In: Journal of Medicinal Chemistry. 2002 ; Vol. 45, No. 12. pp. 2454-2468.

Bibtex

@article{68bf0bd4dab847139077672fa5c43d2c,
title = "Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists: Synthesis, pharmacology, and molecular modeling",
abstract = "A number of analogues of the low-efficacy partial GABAA agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 5), in which the 4-position of the 3-isoxazolol ring was substituted by different groups, were synthesized and tested as GABAA receptor ligands. Substituents of different size and structural flexibility such as alkyl, phenylalkyl, diphenylalkyl, and naphthylalkyl were explored. Pharmacological characterization of the synthesized compounds was carried out using receptor binding assays and by electrophysiological experiments using whole-cell patch-clamp techniques. Whereas none of these compounds significantly affected GABAB receptor sites or GABA uptake, they did show affinity for the GABAA receptor site. While alkyl or benzyl substitution, compounds 7a-h, provided receptor affinities comparable with that of 5 (Ki = 9.1 μM), diphenylalkyl and naphthylalkyl substitution, as in compounds 7m-t, resulted in a dramatic increase in affinity relative to 5. The 3,3-diphenylpropyl and the 2-naphthylmethyl analogues, compounds 7s and 7m, respectively, showed the highest affinities of the series (Ki = 0.074 μM and Ki = 0.049 μM). In whole-cell patch-clamp recordings from cultured cerebral cortical neurons, all of the tested compounds were able to inhibit the effect of the specific GABAA agonist isoguvacine (1), compounds 7m and 7s showing antagonist potency (IC50 = 0.37 μM and IC50 = 0.02 μM) comparable with or markedly higher than that of the standard GABAA antagonist 4 (IC50 = 0.24 μM). Highly potent convulsant activity was demonstrated in mice with compounds 7m (ED50 = 0.024 μmol/kg) and 7s (ED50 = 0.21 μmol/kg) after intracerebroventricular administration, whereas no effects were found after subcutaneous administration. According to a previously proposed pharmacophore model for GABAA receptor agonists, a receptor cavity in the vicinity of the 4-position of the 3-isoxazolol ring in 4-PIOL exists. A molecular modeling study, based on compounds 7o, m,l,q,s, was performed to explore the dimensions and other properties of the receptor cavity. This study demonstrates the importance of the arylalkyl substituents in 7m and 7s and the considerable dimensions of this proposed receptor cavity.",
author = "Bente Fr{\o}lund and J{\o}rgensen, {Anne T.} and Lena Tagmose and Stensb{\o}l, {Tine B.} and Vestergaard, {Henrik T.} and Christine Engblom and Uffe Kristiansen and Connie Sanchez and Povl Krogsgaard-Larsen and Tommy Liljefors",
year = "2002",
month = jun,
day = "6",
doi = "10.1021/jm020027o",
language = "English",
volume = "45",
pages = "2454--2468",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "12",

}

RIS

TY - JOUR

T1 - Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists

T2 - Synthesis, pharmacology, and molecular modeling

AU - Frølund, Bente

AU - Jørgensen, Anne T.

AU - Tagmose, Lena

AU - Stensbøl, Tine B.

AU - Vestergaard, Henrik T.

AU - Engblom, Christine

AU - Kristiansen, Uffe

AU - Sanchez, Connie

AU - Krogsgaard-Larsen, Povl

AU - Liljefors, Tommy

PY - 2002/6/6

Y1 - 2002/6/6

N2 - A number of analogues of the low-efficacy partial GABAA agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 5), in which the 4-position of the 3-isoxazolol ring was substituted by different groups, were synthesized and tested as GABAA receptor ligands. Substituents of different size and structural flexibility such as alkyl, phenylalkyl, diphenylalkyl, and naphthylalkyl were explored. Pharmacological characterization of the synthesized compounds was carried out using receptor binding assays and by electrophysiological experiments using whole-cell patch-clamp techniques. Whereas none of these compounds significantly affected GABAB receptor sites or GABA uptake, they did show affinity for the GABAA receptor site. While alkyl or benzyl substitution, compounds 7a-h, provided receptor affinities comparable with that of 5 (Ki = 9.1 μM), diphenylalkyl and naphthylalkyl substitution, as in compounds 7m-t, resulted in a dramatic increase in affinity relative to 5. The 3,3-diphenylpropyl and the 2-naphthylmethyl analogues, compounds 7s and 7m, respectively, showed the highest affinities of the series (Ki = 0.074 μM and Ki = 0.049 μM). In whole-cell patch-clamp recordings from cultured cerebral cortical neurons, all of the tested compounds were able to inhibit the effect of the specific GABAA agonist isoguvacine (1), compounds 7m and 7s showing antagonist potency (IC50 = 0.37 μM and IC50 = 0.02 μM) comparable with or markedly higher than that of the standard GABAA antagonist 4 (IC50 = 0.24 μM). Highly potent convulsant activity was demonstrated in mice with compounds 7m (ED50 = 0.024 μmol/kg) and 7s (ED50 = 0.21 μmol/kg) after intracerebroventricular administration, whereas no effects were found after subcutaneous administration. According to a previously proposed pharmacophore model for GABAA receptor agonists, a receptor cavity in the vicinity of the 4-position of the 3-isoxazolol ring in 4-PIOL exists. A molecular modeling study, based on compounds 7o, m,l,q,s, was performed to explore the dimensions and other properties of the receptor cavity. This study demonstrates the importance of the arylalkyl substituents in 7m and 7s and the considerable dimensions of this proposed receptor cavity.

AB - A number of analogues of the low-efficacy partial GABAA agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 5), in which the 4-position of the 3-isoxazolol ring was substituted by different groups, were synthesized and tested as GABAA receptor ligands. Substituents of different size and structural flexibility such as alkyl, phenylalkyl, diphenylalkyl, and naphthylalkyl were explored. Pharmacological characterization of the synthesized compounds was carried out using receptor binding assays and by electrophysiological experiments using whole-cell patch-clamp techniques. Whereas none of these compounds significantly affected GABAB receptor sites or GABA uptake, they did show affinity for the GABAA receptor site. While alkyl or benzyl substitution, compounds 7a-h, provided receptor affinities comparable with that of 5 (Ki = 9.1 μM), diphenylalkyl and naphthylalkyl substitution, as in compounds 7m-t, resulted in a dramatic increase in affinity relative to 5. The 3,3-diphenylpropyl and the 2-naphthylmethyl analogues, compounds 7s and 7m, respectively, showed the highest affinities of the series (Ki = 0.074 μM and Ki = 0.049 μM). In whole-cell patch-clamp recordings from cultured cerebral cortical neurons, all of the tested compounds were able to inhibit the effect of the specific GABAA agonist isoguvacine (1), compounds 7m and 7s showing antagonist potency (IC50 = 0.37 μM and IC50 = 0.02 μM) comparable with or markedly higher than that of the standard GABAA antagonist 4 (IC50 = 0.24 μM). Highly potent convulsant activity was demonstrated in mice with compounds 7m (ED50 = 0.024 μmol/kg) and 7s (ED50 = 0.21 μmol/kg) after intracerebroventricular administration, whereas no effects were found after subcutaneous administration. According to a previously proposed pharmacophore model for GABAA receptor agonists, a receptor cavity in the vicinity of the 4-position of the 3-isoxazolol ring in 4-PIOL exists. A molecular modeling study, based on compounds 7o, m,l,q,s, was performed to explore the dimensions and other properties of the receptor cavity. This study demonstrates the importance of the arylalkyl substituents in 7m and 7s and the considerable dimensions of this proposed receptor cavity.

UR - http://www.scopus.com/inward/record.url?scp=0037030612&partnerID=8YFLogxK

U2 - 10.1021/jm020027o

DO - 10.1021/jm020027o

M3 - Journal article

C2 - 12036354

AN - SCOPUS:0037030612

VL - 45

SP - 2454

EP - 2468

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 12

ER -

ID: 312029188